Bio-Rad (BIO) CEO Reports RSU Vesting and Small Sale; Ownership Remains Large
Rhea-AI Filing Summary
Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported changes in his beneficial ownership on September 1, 2025. He acquired 6,353 Class A shares on vesting of restricted stock units and had 3,084 Class A shares disposed of at $297.88 per share. After these transactions he directly owned 444,591 Class A shares. The filing also reports direct ownership of 361,466 Class B shares and indirect holdings of 13,006 Class B shares (by spouse) and 4,060,054 Class B shares (by Blue Raven Partners, L.P.). Several restricted stock unit vesting events are noted, reflecting prior grants from 2021–2023 that vest in annual installments.
Positive
- RSU vesting increased direct Class A holdings by 6,353 shares, reinforcing executive equity alignment
- Substantial long-term holdings retained: 444,591 Class A shares direct and over 4 million Class B shares held indirectly
Negative
- Open-market disposition of 3,084 Class A shares at $297.88 indicates some insider selling activity
Insights
TL;DR: Insider received RSU vesting and executed a small open-market sale; overall ownership remains substantial and governance alignment persists.
The report shows executive compensation settling through restricted stock unit vesting, which increases the reporting person’s direct equity stake by 6,353 Class A shares. A sale of 3,084 Class A shares at $297.88 is recorded, but the reporting person still holds a large position in Class A and significant Class B holdings both directly and indirectly through family and an affiliated partnership. The filing discloses the grant schedules (2021–2023) that vest in four annual installments, indicating multi-year compensation alignment with shareholders.
TL;DR: Transactions are routine compensation vesting plus a minor sale; unlikely to be materially market-moving.
The material items are vesting of previously granted restricted stock units (totaling 6,353 Class A shares acquired on 09/01/2025) and an open-market disposition of 3,084 Class A shares at $297.88. Post-transaction direct ownership of 444,591 Class A shares and large Class B holdings (including 4,060,054 held by Blue Raven Partners, L.P.) suggest continued concentrated insider ownership, which can affect liquidity and control considerations but does not, in itself, indicate a change in corporate strategy or financial condition.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,266 | $0.00 | -- |
| Exercise | Restricted Stock Units | 2,082 | $0.00 | -- |
| Exercise | Restricted Stock Units | 3,005 | $0.00 | -- |
| Exercise | Bio-Rad A Common Stock | 6,353 | $0.00 | -- |
| Tax Withholding | Bio-Rad A Common Stock | 3,084 | $297.88 | $919K |
| holding | Bio-Rad B Common Stock | -- | -- | -- |
| holding | Bio-Rad B Common Stock | -- | -- | -- |
| holding | Bio-Rad B Common Stock | -- | -- | -- |
Footnotes (1)
- Shares of Class A common stock acquired on the vesting of restricted stock units. The reporting person disclaims beneficial ownership of these shares. The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
